Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 20/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22283632 | 0.84 | MGLL (0.45) | MGLL | |
| SCHEMBL22336896 | 0.83 | MGLL (0.44) | MGLL | |
| SCHEMBL22337078 | 0.79 | MGLL (0.41) | MGLL | |
| SCHEMBL20695353 | 0.78 | MGLL (0.41) | MGLL | |
| SCHEMBL20708748 | 0.73 | MGLL (0.38) | MGLL | |
| Acetic Acid SCHEMBL21641089 | 0.73 | MGLL (0.39) | MGLL | |
| SCHEMBL22283760 | 0.71 | MGLL (0.39) | MGLL | |
| SCHEMBL22283759 | 0.71 | MGLL (0.39) | MGLL | |
| SCHEMBL12544783 | 0.69 | — | — | |
| SCHEMBL30984130 | 0.69 | SMN1; SMN2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | MGLL 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.